ArticleCancer medicine2022
Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prognostic role of lymph node regression in patients with esophageal cancer undergoing neoadjuvant therapy.Pathology oncology research : POR · 2024Pooled it
- Reply to: "Methodological Considerations on Prognostic Modeling in Esophageal Cancer-Commentary on Liu et al. (2026)".Annals of surgical oncology · 2026Article
- Do we need to adapt the American Joint Committee on Cancer staging system after neo-adjuvant treatment in esophageal squamous cell carcinoma?Translational cancer research · 2026Article
- Clinical outcomes of esophageal squamous cell carcinoma with pathological complete response after neoadjuvant chemoradiotherapy and surgery.Surgical endoscopy · 2026Article
- Prognostic Value of a Novel Staging System Integrating Lymph Node Station Number and Tumor Regression Grade for Esophageal Cancer Following Neoadjuvant Chemoradiotherapy.Annals of surgical oncology · 2026Article
- Integrating Preoperative Preserved Ratio Impaired Spirometry and Inflammatory Markers to Predict Postoperative Complications and Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.Journal of inflammation research · 2026Article
- Positive Lymph Node Status Before and After Neoadjuvant Chemoradiotherapy Improves Prediction of Disease-Free Survival in Esophageal Squamous Cell Carcinoma Patients.Annals of surgical oncology · 2025Article
- Article
- Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.BMC cancer · 2025Article
- The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study.Frontiers in immunology · 2025Article
- The neoadjuvant esophageal score: a prognostic tool for predicting survival and postoperative complications in esophageal squamous cell carcinoma.Frontiers in immunology · 2025Article
- Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.Annals of surgical oncology · 2024Article
- Prognostic role of pathologic status other than complete response after neoadjuvant therapy followed by surgery in esophageal squamous cell carcinoma.Esophagus : official journal of the Japan Esophageal Society · 2024Article
- Development and Validation of a Recurrence-Free Survival Prediction Model for Locally Advanced Esophageal Squamous Cell Carcinoma with Neoadjuvant Chemoradiotherapy.Annals of surgical oncology · 2024Article
- Article
- The area of residual tumor predicts esophageal squamous cell carcinoma prognosis following neoadjuvant chemotherapy.Journal of cancer research and clinical oncology · 2023Article
- Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe aimed to elucidate the prognostic value of tumor regression grade (TRG) combined with lymph node status compared with the 8th edition of the ypTNM staging system in patients with advanced esophageal squamous cell cancer (ESCC) after neoadjuvant chemoradiotherapy (nCRT).
methodsWe enrolled 325 patients with ESCC who underwent nCRT followed by complete resection. We adopted the modified Schneider TRG system, with high (ypT0N0), mid (ypT0N+ or ypT + N0), and low (ypT + N+). After developing a multivariable Cox model, the discrimination ability of the ypStage and TRG systems was evaluated using the Akaike Information Criterion (AIC) and R
resultsThe mean duration of follow-up was 56.7 ± 43.3 months. The survival curves between the adjacent groups of TRG were significantly different for both overall survival (OS) and recurrence-free survival (RFS). However, there were no significant differences between ypStages II and III for OS (p = 0.683) or RFS (p = 0.760). The TRG system also had a discrimination ability in patients with ypStage I (p < 0.001 for both OS and RFS) and ypStage III (p = 0.045 for OS and 0.042 for RFS). Compared with the ypTNM staging system, the modified TRG had a lower AIC value (1835.99 vs. 1852.02) and a higher R
conclusionsFor patients with ESCC who underwent esophagectomy following nCRT, the modified Schneider TRG system may complement the ypStage and help clinicians select the most appropriate postoperative treatment and surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.